The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey

Published:2016-04-12 Issue:4 Volume:26 Page:e12490
ISSN:0961-5423
Container-title:European Journal of Cancer Care
language:en
Short-container-title:Eur J Cancer Care

Author:

Lebret T.¹²,Casas A.³,Cavo M.⁴,Woll P.J.⁵,Deleplace C.⁶,Kennedy C.⁷,Schoen P.⁸,Jackisch C.⁹

Affiliation:

1. Departement d'Urologie; Hôpital Foch; Suresnes France

2. Université Versaille St Quentin en Yvelines; Versailles France

3. Servicio de Oncología Médica; Hospital Universitario Virgen del Rocío; Sevilla Spain

4. Departimento di Ematologia e Scienze Oncologiche; Universita di Bologna; Bologna Italy

5. University of Sheffield Academic Unit of Clinical Oncology; Weston Park Hospital; Sheffield UK

6. Kantar Health France; Montrouge Cedex France

7. Amgen Ltd; Uxbridge UK

8. Amgen (Europe) GmbH; Zug Switzerland

9. Department of Obstetrics and Gynecology; Klinikum Offenbach Frauenklinik Starkenburgring; Offenbach Germany

Funder

Amgen

Publisher

Wiley

Subject

Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ecc.12490/fullpdf

Reference53 articles.

1. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel;Aapro;Annals of Oncology,2008

2. Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases;Aapro;Oncologist,2010

3. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group;Berenson;New England Journal of Medicine,1996

4. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma;Berenson;Journal of Clinical Oncology,2002

5. Effectiveness and cost of bisphosphonate therapy in tumor bone disease;Body;Cancer,2003

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study;Journal of Bone Oncology;2022-04

2. The prostate cancer landscape in Europe: Current challenges, future opportunities;Cancer Letters;2022-02

3. Targeted Radionuclide Therapy for Bone Metastasis;Nuclear Oncology;2022

4. Targeted Radionuclide Therapy for Bone Metastasis;Nuclear Oncology;2022

5. Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events;The European Journal of Health Economics;2021-01-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3